Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Mar 17;33(2):281-5.
doi: 10.1016/j.pnpbp.2008.11.016. Epub 2008 Dec 7.
Affiliations
- PMID: 19110026
- DOI: 10.1016/j.pnpbp.2008.11.016
Randomized Controlled Trial
Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients
Ayse Devrim Başterzi et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009.
Abstract
Background: Several studies demonstrated that depressed patients had low serum BDNF levels which correlated with the severity of their depression, and antidepressant treatment increases levels of serum BDNF in depressed patients. It was speculated that agents acting on both noradrenergic and serotonergic transporters might have a greater influence on BDNF levels. The aim of our study was to determine effects of venlafaxine vs. fluoxetine on serum BDNF levels in depressive patients.
Methods: Forty-three patients diagnosed as major depressive disorder according to DSM-IV are included in the study. Forty-three patients were randomized to take fluoxetine (22 cases) or venlafaxine (21 cases). Serum levels of BDNF were measured by ELISA at baseline and 6 weeks after the start of treatment.
Results: Baseline levels of BDNF were not significantly different between the patient group and the controls. But male patients and the male controls showed statistical differences with respect to baseline BDNF levels. BDNF levels of the patient group did not change with treatment. Yet, the increase of BDNF levels was close to statistically significant in the fluoxetine group, whereas not significant in the venlafaxine group. There were no significant differences in baseline and 6th week BDNF levels between the responders and the non-responders.
Conclusion: Further studies controlling for a wide variety of confounding variables are needed, which may help to reach a clear conclusion about the potential of BDNF as a biomarker for depression or as a predictor of antidepressant efficacy.
Similar articles
- Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.
Ristevska-Dimitrovska G, Shishkov R, Gerazova VP, Vujovik V, Stefanovski B, Novotni A, Marinov P, Filov I. Ristevska-Dimitrovska G, et al. Psychiatr Danub. 2013 Jun;25(2):123-7. Psychiatr Danub. 2013. PMID: 23793275 - Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J. Costa e Silva J. J Clin Psychiatry. 1998 Jul;59(7):352-7. doi: 10.4088/jcp.v59n0703. J Clin Psychiatry. 1998. PMID: 9714263 Clinical Trial. - Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
Judge R, Wagner BE. Judge R, et al. J Clin Psychiatry. 1999 Nov;60(11):795-6. doi: 10.4088/jcp.v60n1121. J Clin Psychiatry. 1999. PMID: 10584775 No abstract available. - Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K, Perry CM. Wellington K, et al. CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review. - Clinical evaluation of venlafaxine.
Ballenger JC. Ballenger JC. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. doi: 10.1097/00004714-199606002-00007. J Clin Psychopharmacol. 1996. PMID: 8784646 Review.
Cited by
- Fluoxetine versus other types of pharmacotherapy for depression.
Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C. Magni LR, et al. Cochrane Database Syst Rev. 2013 Jul 17;2013(7):CD004185. doi: 10.1002/14651858.CD004185.pub3. Cochrane Database Syst Rev. 2013. PMID: 24353997 Free PMC article. Review. - BDNF plasma levels variations in major depressed patients receiving duloxetine.
Fornaro M, Escelsior A, Rocchi G, Conio B, Magioncalda P, Marozzi V, Presta A, Sterlini B, Contini P, Amore M, Fornaro P, Martino M. Fornaro M, et al. Neurol Sci. 2015 May;36(5):729-34. doi: 10.1007/s10072-014-2027-7. Epub 2014 Dec 11. Neurol Sci. 2015. PMID: 25501804 - Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD).
Mosiołek A, Mosiołek J, Jakima S, Pięta A, Szulc A. Mosiołek A, et al. J Clin Med. 2021 Jul 30;10(15):3377. doi: 10.3390/jcm10153377. J Clin Med. 2021. PMID: 34362162 Free PMC article. Review. - Advances in the Preclinical Study of Some Flavonoids as Potential Antidepressant Agents.
German-Ponciano LJ, Rosas-Sánchez GU, Rivadeneyra-Domínguez E, Rodríguez-Landa JF. German-Ponciano LJ, et al. Scientifica (Cairo). 2018 Feb 1;2018:2963565. doi: 10.1155/2018/2963565. eCollection 2018. Scientifica (Cairo). 2018. PMID: 29623232 Free PMC article. Review. - Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression.
Zhou C, Zhong J, Zou B, Fang L, Chen J, Deng X, Zhang L, Zhao X, Qu Z, Lei Y, Lei T. Zhou C, et al. PLoS One. 2017 Feb 27;12(2):e0172270. doi: 10.1371/journal.pone.0172270. eCollection 2017. PLoS One. 2017. PMID: 28241064 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources